Printer Friendly

BARR ANNOUNCES SECOND QUARTER SALES AND EARNINGS

 BARR ANNOUNCES SECOND QUARTER SALES AND EARNINGS
 POMONA, N.Y., Feb. 10 /PRNewswire/ -- Barr Laboratories, Inc.


(AMEX: BRL) announced financial results for its second quarter ended Dec. 31, 1991:
 Net sales for the second fiscal quarter increased to $30.6 million as compared to $25.8 million, an increase of 19 percent over the comparable quarter last year. Net income for the second quarter was $728,000 or $.08 per share as compared to net income of $1,910,000 or $.25 per share for the comparable quarter last year.
 Net sales for the six months ended Dec. 31, 1991 were $59.6 million as compared to $44.6 million, an increase of 34 percent over the comparable period last year. Net income for the period was $1,775,000 or $.20 per share as compared to $2,258,000 or $.30 per share for the comparable period last year.
 The increase in sales was due to the stronger demand for several of the company's products.
 Operating results for both the current quarter and the current year- to-date period were somewhat improved over the comparative periods last year as a result of higher sales, better gross margins, which were offset in part by additional operating expenses and increased research and development expenditures. Net earnings for both the current quarter and the current year-to-date period were significantly affected by a provision for an adverse decision on a 1989 breach of contract lawsuit of $1.6 million or $.12 per share. The company is in the process of appealing this decision. Also affecting net income were regulatory and compliance expenses for certain non-recurring charges of $1.4 million or $.10 per share. The majority of these expenses were related to an inspection of the Food and Drug Administration (FDA). Discussions with the FDA continue and the company hopes it can resolve all remaining points scientifically, without litigation.
 Barr Laboratories remains committed to its future in the generic industry as evidenced by its increase in research and development expenditures for the six months ended Dec. 31, 1991 to $3.9 million, a 50 percent increase over the same period last year.
 Barr is a prime manufacturer of a broad range of multi-source pharmaceutical products with manufacturing facilities located in Northvale, N.J. and Pomona, N.Y.
 BARR LABORATORIES, INC. AND SUBSIDIARIES
 Consolidated Statement of Earnings
 (Dollars in thousands, except per share amounts, unaudited)
 Periods ended Three months Six months
 Dec. 31 1991 1990 1991 1990
 Net sales $30,633 $25,793 $59,602 $44,578
 Costs and expenses:
 Cost of sales 18,518 16,158 37,513 29,119
 Distribution 969 755 1,910 1,454
 Marketing and sales 1,945 1,560 3,795 2,749
 Research and development 1,817 1,386 3,948 2,601
 General and administrative 2,610 2,395 5,371 4,098
 Interest expense, net 619 507 1,247 973
 Operating results 4,155 3,032 5,818 3,584
 Provision for lawsuit 1,600 -- 1,600 --
 Regulatory and compliance
 expenses 1,400 -- 1,400 --
 Earnings before income taxes 1,155 3,032 2,818 3,584
 Income tax provision 427 1,122 1,043 1,326
 Net earnings 728(A) 1,910 1,775(A) 2,258
 Net earnings per common
 share and common share
 equivalents 0.08 0.25 0.20 0.30
 Weighted average number
 of common share and common
 share equivalents 8,672,576 7,609,549 8,662,813 7,608,266
 (A) Includes $1.6 million charge or $.12 per share for an adverse decision on breach of contract lawsuit and $1.4 million charge or $.10 per share for certain non-recurring regulatory and compliance issues.
 -0- 2/11/92
 /CONTACT: Louis J. Guerci, vice president of finance of Barr Laboratories, 914-362-1100/
 (BRL) CO: Barr Laboratories, Inc. ST: New York IN: MTC SU: ERN


KD-OS -- NY061 -- 8342 02/10/92 13:45 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 10, 1992
Words:653
Previous Article:GENETICS INSTITUTE SHARES NOW TRADING UNDER NEW NASDAQ SYMBOL -- GENIZ
Next Article:TEMCO REPORTS RESULTS FOR THE YEAR ENDED SEPT. 30, 1991
Topics:


Related Articles
BARR LABORATORIES RELEASES FIRST QUARTER FINANCIAL RESULTS
BARR LABORATORIES RELEASES THIRD QUARTER FINANCIAL RESULTS
BARR RELEASES SALES AND EARNINGS FOR FISCAL YEAR ENDED JUNE 30, 1992
BARR LABORATORIES RELEASES SECOND QUARTER FINANCIAL RESULTS
BARR REPORTS DOUBLE DIGIT INCREASES FOR SECOND QUARTER SALES AND EARNINGS; FIFTH CONSECUTIVE QUARTER OF GROWTH
Barr Laboratories Reports $0.15 EPS for Second Quarter 1997; Sales of $67 Million Represent 17% Increase
Barr Laboratories Announces $1.00 EPS for Third Quarter 1997; Board Authorizes 3-for-2 Stock Split in Recognition of Milestone Achievements
Barr Laboratories Reports Second Quarter EPS of $0.31 vs. $0.10 Last Year; Revenues Increase 37% to $92 Million; Net Earnings Climb 184% to $6 Million
Barr Laboratories' First Quarter 1999 EPS Increases to $0.48; Products Launched in Past 12 Months Drive Earnings Increase.
Barr Laboratories' Second Quarter EPS Increases 93% to $0.52; 68% Increase in Sales of Manufactured Products Drives Impressive Performance.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters